These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 4609353)
1. Active specific immunotherapy for acute myelogenous leukaemia. Powles R Johns Hopkins Med J Suppl; 1974; 3():333-40. PubMed ID: 4609353 [No Abstract] [Full Text] [Related]
2. Immunotherapy of acute myelogenous leukemia in man. Powles R Natl Cancer Inst Monogr; 1973 Dec; 39():243-7. PubMed ID: 4595324 [No Abstract] [Full Text] [Related]
4. The effect of immunotherapy on survival of patients with acute myelogenous leukaemia after relapse. Powles R; Toy JL Haematologia (Budap); 1976; 10(1):5-9. PubMed ID: 1070466 [TBL] [Abstract][Full Text] [Related]
5. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer. Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074 [No Abstract] [Full Text] [Related]
6. Treatment of the acute leukemias. Bernard J; Jacquillat C; Weil M Semin Hematol; 1972 Apr; 9(2):181-91. PubMed ID: 4553226 [No Abstract] [Full Text] [Related]
8. HL-A antibody response in patients with acute myelogenous leukaemia treated by immunotherapy. Klouda TP; Lawler SD; Powles RL; Oliver RT; Grant CK Transplantation; 1975 Mar; 19(3):245-9. PubMed ID: 1094639 [No Abstract] [Full Text] [Related]
9. Immunotherapy for acute myelogenous leukemia using irradiated and unirradiated leukemia cells. Powles R Cancer; 1974 Oct; 34(4 Suppl):suppl:1558-62. PubMed ID: 4608692 [No Abstract] [Full Text] [Related]
10. Perspectives and prospectives in the management of acute leukemia. Henderson ES Hamatol Bluttransfus; 1976; 19():305-10. PubMed ID: 795745 [No Abstract] [Full Text] [Related]
12. Advances in the treatment of acute myelogenous leukemia. Gale RP N Engl J Med; 1979 May; 300(21):1189-99. PubMed ID: 372809 [No Abstract] [Full Text] [Related]
13. Chemoimmunotherapy for maintenance in acute myeloblastic leukemia. Whiteside MG; Cauchi MN; Paton C; Stone J Cancer; 1976 Oct; 38(4):1581-6. PubMed ID: 1068741 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for acute myelogenous leukaemia. Powles R Br J Cancer Suppl; 1973 Aug; 1():262-5. PubMed ID: 4531352 [No Abstract] [Full Text] [Related]
15. The place of immunological methods of treatment in the management of acute leukaemia. Powles RL; Russell JA Hamatol Bluttransfus; 1976; 19():297-304. PubMed ID: 795744 [No Abstract] [Full Text] [Related]
16. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia]. Malpas J; Mathé G; Hayat M Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741 [No Abstract] [Full Text] [Related]
17. BCG immunotherapy of rat tumors of defined immunogenicity. Baldwin RW; Pimm MV Natl Cancer Inst Monogr; 1973 Dec; 39():11-9. PubMed ID: 4595312 [No Abstract] [Full Text] [Related]
18. Granulocyte function in myeloblastic leukaemia. Wilkinson PM; Sumner C; Delamore IW; Geary CG; Milner GR Br J Cancer; 1975 Nov; 32(5):574-7. PubMed ID: 764849 [TBL] [Abstract][Full Text] [Related]